CA Patent

CA2714445C — Treatment of metastatic stage prostate cancer with degarelix

Assigned to Ferring International Center SA · Expires 2018-01-16 · 8y expired

What this patent protects

Compositions comprising degarelix for the treatment of metastatic stage prostate cancer in a subject are provided.

USPTO Abstract

Compositions comprising degarelix for the treatment of metastatic stage prostate cancer in a subject are provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA2714445C
Jurisdiction
CA
Classification
—
Expires
2018-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Ferring International Center SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.